Keywords: Roche, Intermune, Licensing, Danoprevir, Pirfenidone, Esbriet, Hepatitis C, Lung disease, Pulmonary fibrosis
Roche acquires global rights to InterMune’s hep C drug danoprevir for $175 million
Article | 07 October 2010
US biotech firm InterMune (Nasdaq: ITMN) has sold worldwide development and commercialization rights to its hepatitis C drug candidate danoprevir ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
